|Day Low/High||41.87 / 42.40|
|52 Wk Low/High||34.32 / 46.47|
Pfizer may be done with its two-month correction but the uptrend may not resume right away.
When the stock's inexpensive, hated and devoid of love -- that's when.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
This is the kind of reversal that happens in a bull market.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer pushes higher on price increases.
A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Let's check our indicators.
Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Some groups that have been in horrendous bear market mode finally caught a bid.
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
It becomes difficult for me to tell you where to run in these markets...